Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19147767
Singh RP, et al. (2009) Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15, 613-21 19147767
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

S218-p - MEK1 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

S222-p - MEK1 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase
silibinin inhibit treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin increase
silibinin inhibit treatment-induced increase

Y701-p - STAT1 (human)
Modsite: DGPkGtGyIktELIs SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): Y701‑p, STAT1 iso2 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

S727-p - STAT1 (human)
Modsite: TDNLLPMsPEEFDEV SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): S727‑p, STAT1 iso2 (human): , STAT1 (mouse): S727‑p, STAT1 (rat): S727‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

Y705-p - STAT3 (human)
Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

S727-p - STAT3 (human)
Modsite: NtIDLPMsPRTLDSL SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 iso3 (human): , STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase

Y694-p - STAT5A (human)
Modsite: LAkAVDGyVkPQIkQ SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  prostate cancer
Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Comments:  tumor xenograft model
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silibinin inhibit treatment-induced increase